BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neuren Pharmaceuticals Limited Raises A$7.1M in Rights Issue


2/11/2008 12:07:00 PM

Neuren Pharmaceuticals (ASX:NEU) announces the completion of its rights issue, with the placement of 10,022,787 ordinary shares to Taylor Collison Limited and its sub-underwriters. In total A$7.1 million was raised and 50,700,000 ordinary shares were issued under the offer, with 89% taken up by existing shareholders.

In addition, as the amount raised was in excess of US$5 million, the convertible notes previously issued by Neuren in conjunction with the acquisition of Hamilton Pharmaceuticals in October 2007, together with accumulated interest, have converted to 24,525,060 ordinary shares which have been allotted to the noteholders. As a result two leading US based life sciences investors, CNF Investments and Vivo Ventures, have become significant shareholders in Neuren through their associated funds.

Neuren’s Chairman, Dr Robin Congreve said: "The continuing support and confidence from Neuren's shareholders is very gratifying and very much appreciated. The Company is extremely pleased with progress in it clinical programmes and is optimistic about the returns they can provide for shareholders.”

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of brain injury and diseases and metabolic disorders. The Neuren portfolio consists of eight product families, targeting markets with large unmet needs and limited competition. Neuren has four lead candidates, Glypromate®, MotivaTM, NNZ-2566 and NNZ-2591 targeting a range of acute and chronic neurological conditions.

For more information, please visit Neuren’s website at www.neurenpharma.com.

Contact details: Neuren Media and investor relations Dr. Parmjot Bains, Co-CEO M: +61 488 494 353 (Au)

Mr Larry Glass, Co-CEO T: +1 301 758 2987 (USA)

NZ office: T: 1 800 259 181 (Australia) T: +64 9 529 3940



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES